Lv2
168 积分 2024-07-19 加入
26-A-11163-ACC PHASE 1 UPDATE: THE NOVEL ORAL PCSK9 INHIBITOR ENLICITIDE DOES NOT AFFECT THE PHARMACOKINETICS OF NARROW THERAPEUTIC INDEX CONCOMITANT MEDICATIONS
1个月前
已关闭
Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates
1个月前
已完结
How to Develop Robust Solid Oral Dosage Forms from Conception to Post-Approval
1个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
4个月前
已完结
Pharmacokinetic Evaluation of Thermosensitive Sustained Release Formulations Developed for Subcutaneous Delivery of Protein Therapeutics
6个月前
已关闭
POS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
6个月前
已关闭
Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices
6个月前
已完结
Bioequivalence study of nabumetone tablets in man
7个月前
已完结
Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model
8个月前
已完结
Development of chitosan-based nanoparticles through inter-polymeric complexation for oral drug delivery
9个月前
已完结
皖公网安备34019202002308
